| 0.34 -0.009 (-2.44%) | 12-05 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.45 | 1-year : | 0.53 |
| Resists | First : | 0.38 | Second : | 0.45 |
| Pivot price | 0.32  |
|||
| Supports | First : | 0.32 | Second : | 0.28 |
| MAs | MA(5) : | 0.34 |
MA(20) : | 0.32 |
| MA(100) : | 0.31 |
MA(250) : | 0.62 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.8 |
D(3) : | 69.6 |
| RSI | RSI(14): 54.7 |
|||
| 52-week | High : | 1.46 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRXP ] has closed below upper band by 34.5%. Bollinger Bands are 3.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.38 - 0.38 | 0.38 - 0.38 |
| Low: | 0.32 - 0.32 | 0.32 - 0.32 |
| Close: | 0.34 - 0.34 | 0.34 - 0.34 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Mon, 27 Nov 2023
NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference - Yahoo Finance
Mon, 13 Nov 2023
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - PR Newswire
Tue, 07 Nov 2023
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 - Yahoo Finance
Mon, 06 Nov 2023
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to ... - PR Newswire
Thu, 26 Oct 2023
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the ... - PR Newswire
Tue, 03 Oct 2023
NRx Pharma (NRXP) to Initiate Clinical Study on NRX-101, Stock Up - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 85 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 36 (%) |
| Held by Institutions | 4.2 (%) |
| Shares Short | 1,540 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -109 % |
| Return on Equity (ttm) | -682.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | -4.25 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|